Georges Gemayel - Nov 8, 2024 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role: Director
Signature: /s/ Timothy C. Dec, as attorney-in-fact
Stock symbol: SUPN
Transactions as of: Nov 8, 2024
Transactions value $: -$267,949
Form type: 4
Date filed: 11/12/2024, 04:13 PM
Previous filing: Nov 8, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SUPN	Common Stock	Options Exercise	$124K	+10.8K	+81.01%	$11.46	24.1K	Nov 8, 2024	Direct
transaction	SUPN	Common Stock	Sale	-$392K	-10.8K	-44.76%	$36.30	13.3K	Nov 8, 2024	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SUPN	Director Stock Option (Right to Buy)	Options Exercise	$0	-10.8K	-100%	$0.00	0	Nov 8, 2024	Common Stock	10.8K	$11.46	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person exercised the options indicated herein and sold the underlying shares prior to the expiration of such options on March 23, 2025.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.01 to $36.57. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Content

The Reporting Person exercised the options indicated herein and sold the underlying shares prior to the expiration of such options on March 23, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.01 to $36.57. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.